| scholarly article | Q13442814 |
| P50 | author | Ravi K V Bhongir | Q85276206 |
| Praveen Papareddy | Q58658896 | ||
| P2093 | author name string | Artur Schmidtchen | |
| Martin Malmsten | |||
| Matthias Mörgelin | |||
| Martina Kalle | |||
| P2860 | cites work | Histidine-rich glycoprotein protects from systemic Candida infection | Q24313429 |
| Highly selective end-tagged antimicrobial peptides derived from PRELP | Q28476835 | ||
| Proteolysis of human thrombin generates novel host defense peptides | Q29871443 | ||
| Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. | Q31835224 | ||
| Antimicrobial activity of human prion protein is mediated by its N-terminal region | Q33509013 | ||
| Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment | Q33526956 | ||
| Antithrombin replacement in patients with sepsis and septic shock | Q33636213 | ||
| Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis | Q34001696 | ||
| C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules | Q34107512 | ||
| Antimicrobial proteins and peptides in host defense | Q34223226 | ||
| Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial | Q34518326 | ||
| Antithrombin III in Sepsis. New evidences and open questions | Q34656175 | ||
| Antithrombin: a new look at the actions of a serine protease inhibitor | Q35004303 | ||
| Interactions between Coagulation and Inflammation | Q35585029 | ||
| Heparin-binding domains in vascular biology | Q35825233 | ||
| Regulation of thrombin activity--pharmacologic and structural aspects | Q36720111 | ||
| Serpins in thrombosis, hemostasis and fibrinolysis | Q36884340 | ||
| Proteolytic activation transforms heparin cofactor II into a host defense molecule | Q36914757 | ||
| Activation of the complement system generates antibacterial peptides | Q37695583 | ||
| Host defense peptides and their antimicrobial-immunomodulatory duality | Q37786712 | ||
| Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity | Q38293560 | ||
| Intracellular receptor for human host defense peptide LL-37 in monocytes | Q39824888 | ||
| Therapeutic potential of HDPs as immunomodulatory agents | Q39907609 | ||
| Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. | Q40321158 | ||
| An overview of the mechanism of action of antithrombin and its inherited deficiency states. | Q40753967 | ||
| Coagulation inhibitor substitution during sepsis | Q40990081 | ||
| Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action | Q41456132 | ||
| Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats | Q42199996 | ||
| Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies | Q44075032 | ||
| Human antithrombin III-derived heparin-binding peptide, a novel heparin antagonist | Q44597765 | ||
| Antimicrobial activities of heparin-binding peptides | Q44629787 | ||
| Probing the heparin-binding domain of human antithrombin III with V8 protease | Q45302282 | ||
| Comparison of the helix-coil transition of a titrating polypeptide in aqueous solutions and at the air-water interface | Q46505055 | ||
| Domain 5 of high molecular weight kininogen is antibacterial | Q46642869 | ||
| Therapeutic applications of antithrombin concentrates in systemic inflammatory disorders. | Q47851737 | ||
| Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. | Q48020761 | ||
| Heparin binding protein is increased in chronic leg ulcer fluid and released from granulocytes by secreted products of Pseudomonas aeruginosa. | Q51642205 | ||
| Engineering D-helix of antithrombin in alpha-1-proteinase inhibitor confers antiinflammatory properties on the chimeric serpin. | Q53621386 | ||
| Bacterial killing by heparin-binding peptides from PRELP and thrombospondin. | Q54464584 | ||
| A heparin binding site in antithrombin III. Identification, purification, and amino acid sequence | Q68182117 | ||
| Computed circular dichroism spectra for the evaluation of protein conformation | Q71225133 | ||
| Attenuating effect of antithrombin III on the fibrinolytic activation and microvascular derangement in rat gastric mucosa | Q72381283 | ||
| The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/endothelial cell interaction and microvascular perfusion failure | Q73226945 | ||
| Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli | Q73426853 | ||
| Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood | Q73436045 | ||
| Measurement of free radicals and NO by chemiluminescence to identify the reperfusion injury in renal transplantation | Q74060471 | ||
| Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells | Q74097923 | ||
| Degradation of antiproteinases, complement and fibronectin in chronic leg ulcers | Q74211300 | ||
| Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis | Q77168946 | ||
| Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37 | Q77630845 | ||
| LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature | Q84541002 | ||
| P433 | issue | 43 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 29790-29800 | |
| P577 | publication date | 2014-09-08 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Antimicrobial effects of helix D-derived peptides of human antithrombin III | |
| P478 | volume | 289 |
| Q33737867 | Aggregation of thrombin-derived C-terminal fragments as a previously undisclosed host defense mechanism. |
| Q54267933 | An ecoimmunological approach to study evolutionary and ancient links between coagulation, complement and Innate immunity. |
| Q90005460 | Antimicrobial Peptide JH-3 Effectively Kills Salmonella enterica Serovar Typhimurium Strain CVCC541 and Reduces Its Pathogenicity in Mice |
| Q89950751 | Antithrombin: An anticoagulant, anti-inflammatory and antibacterial serpin |
| Q48502611 | Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions |
| Q47126929 | Immunohaemostasis: a new view on haemostasis during sepsis |
| Q40936407 | NLF20: an antimicrobial peptide with therapeutic potential against invasive Pseudomonas aeruginosa infection. |
| Q28597180 | Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections |
Search more.